CD34 positive blood cells for allogeneic progenitor and stem cell transplantation.

摘要: The transplantation of allogeneic peripheral blood progenitor cells (PBPC) provides complete and sustained hematopoietic lymphopoietic engraftment. In healthy donors, large amounts PBPC can be mobilized with growth factors. However, the high content immunocompetent T-cells in apheresis products may expose recipients to an elevated risk acute chronic graft-versus-host disease. Thus, use appropriate T-cell reduction, but not depletion might reduce this risk. hazards graft rejection a higher relapse rate avoided by maintaining portion graft. positive selection CD34+ from preparations simultaneously approximately 1000-fold reduction T-cells. These purified containing committed pluripotent stem are suitable for used following instances: 1. As cell instead bone marrow cells, HLA-identical family donors; 2. increasing numbers HLA-mismatched or three HLA-loci different donors order incidence without number; 3. boosting poor function same 4. volunteer matched unrelated 5. split T-cells; 6. addition ex vivo expanded transplantation; 7. generation antigen specific immune effector presenting therapy.